Biogen
ProfileJobs (490)

Biogen

Suggest Edit
    • Healthbiotechdrug developmentpharma
    Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
    Revenue(FY, 2016)
    $11.4 B
    Market capitalization(2018-06-14)
    $64.5 B
    Training Provided, no. of people(FY, 2016)
    40 K
    Type
    Public
    HQ
    Cambridge, US
    Founded
    1978
    Size (employees)
    7,300 (est)-1%
    Website
    biogen.com
    Biogen was founded in 1978 and is headquartered in Cambridge, US
    Report incorrect company information

    Key People/Management at Biogen

    Michel Vounatsos

    Michel Vounatsos

    CEO
    Susan Alexander

    Susan Alexander

    EVP
    Jeffrey Capello

    Jeffrey Capello

    EVP
    Michael Ehlers

    Michael Ehlers

    EVP
    Ginger Gregory

    Ginger Gregory

    EVP
    Chirfi Guindo

    Chirfi Guindo

    EVP
    Show more

    Biogen Office Locations

    Biogen has an office in Cambridge
    Cambridge, US (HQ)
    225 Binney St
    Show all (1)
    Report incorrect company information

    Biogen Financials and Metrics

    Biogen Financials

    Biogen's revenue was reported to be $11.45 b in FY, 2016 which is a 6.4% increase from the previous period.
    USD

    Revenue (Q1, 2017)

    		2.8 b

    Net income (Q1, 2017)

    		747.5 m

    EBIT (Q1, 2017)

    		1 b

    Market capitalization (14-Jun-2018)

    		64.5 b

    Closing share price (14-Jun-2018)

    		305.7

    Cash (31-Mar-2017)

    		924 m
    Biogen's current market capitalization is $64.5 b.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Revenue

    		6.9 b9.7 b10.8 b11.4 b

    Revenue growth, %

    		40%11%6%

    General and administrative expense

    		1.9 b

    R&D expense

    		2 b
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Revenue

    		2.4 b2.5 b2.6 b2.6 b2.8 b2.7 b2.9 b3 b2.8 b

    General and administrative expense

    		576.6 m570.4 m560.4 m491.9 m477.8 m497.3 m492.4 m462.7 m499.1 m

    R&D expense

    		447.3 m417.2 m460.5 m490.7 m519.9 m437.3 m473.1 m529 m423.4 m

    Operating expense total

    		1 b987.6 m1 b982.6 m997.7 m934.6 m965.5 m991.7 m922.5 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Cash

    		602.6 m1.2 b1.3 b2.3 b

    Accounts Receivable

    		824.4 m1.3 b1.2 b1.4 b

    Inventories

    		659 m804 m893.4 m1 b

    Current Assets

    		3.2 b4.7 b6.7 b8.7 b
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Cash

    		863.2 m1.2 b1.5 b1.3 b4.1 b1.1 b1.4 b2.1 b924 m

    Accounts Receivable

    		1 b1.1 b1.4 b1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b

    Inventories

    		715.9 m753.1 m825.3 m865.7 m918.9 m964.6 m996.4 m1 b921.6 m

    Current Assets

    		3.9 b4.4 b5.3 b5.6 b9.3 b7.2 b7.4 b8.1 b6.9 b
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    		1.9 b2.9 b3.6 b3.7 b

    Depreciation and Amortization

    		688.2 m600.4 m682.7 m

    Inventories

    		(240 m)(190 m)(170 m)(165.6 m)
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    		723.1 m856.1 m820.2 m924.8 m1 b969.2 m1 b1 b747.5 m

    Inventories

    		865.7 m918.9 m964.6 m996.4 m1 b921.6 m

    Accounts Payable

    		282.7 m251.2 m271.3 m225.9 m274 m316.4 m
    show all
    USDY, 2017

    Revenue/Employee

    		379.8 k

    Financial Leverage

    		1.8 x
    Show all financial metrics

    Biogen Operating Metrics

    Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
    FY, 2016

    Phase I Trials Products

    		4

    Phase II Trials Products

    		10

    Phase III Trials Products

    		2

    Training Provided, no. of people

    		40 k
    Show all operating metrics

    Biogen Acquisitions / Subsidiaries

    Acquired CompanyDateDeal Size
    Karyopharm Therapeutics January 25, 2018$10 m
    Report incorrect company information

    Competitors

    Shire
    Health - Public
    Bayer
    Health - Public
    Amgen
    Health - Public
    Gilead Sciences
    Health - Public
    Compare competitors

    Biogen Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Biogen News and Updates

    June 15, 2018

    Biogen (BIIB) Presents At 2018 Annual SMA Conference - Slideshow

    June 13, 2018

    Biogen (BIIB) Investor Presentation - Slideshow

    June 07, 2018

    Your Daily Pharma Scoop: Endra Zooms, Biogen And Eisai Present Positive Results, Synergy Moves Up

    June 01, 2018

    Now that Ironwood's spinning off R&D, activist Alex Denner is easing up

    Ironwood’s activist investor likes what it’s seen recently from the Massachusetts drugmaker—so much so that Sarissa Capital held off on pushing for a spot on the company's board. What's to like? Ironwood's plan to split into two companies, one focused mostly on marketed meds, the other on pipeline.
    May 31, 2018

    Biogen poaches Pfizer dealmaker Dan Karp for stepped-up M&A push

    Want to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing. On Thursday, the big biotech said it recruited veteran Dan Karp in a revamp of its BD and corporate strategy team.
    May 29, 2018

    Pemphigus Vulgaris -Therapeutics Development in depth with Future Prospects by Leading Key Players: Biogen Inc, HanAll Biopharma, Immunomedics

    Pemphigus Vulgaris -Therapeutics Development by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday
    Show more
    Report incorrect company information
    Download PDF